You can now read 5 articles in a month for free on Read as much as you want anywhere and anytime for just 99¢.

FDA puts ‘partial hold’ on Vertex study

Federal regulators have put a “partial clinical hold” on a mid-stage study of an experimental oral drug developed by Vertex Pharmaceuticals Inc. to treat hepatitis C.

The move will prevent the Cambridge company from giving clinical trial patients 200 milligram doses of the pill, which would be used in combination with other oral therapies to treat the virus.

Continue reading below

Vertex already has an oral hepatitis C treatment on the market, but it is used in combination with an injectable drug.

A Vertex spokesman, Zach Barber, said that the Food and Drug Administration ordered the hold after three patients in a European trial showed elevated liver enzymes — a potential marker of liver damage — when taking 400 milligram doses.

The US trial was designed to use only 100 milligram and 200 milligram dosing levels, he said. Vertex will continue with its 100 milligram dosing.

“The FDA has requested data from us, and we’ll be providing that data on an ongoing basis” to gauge the effect of the drug candidate on patients, Barber said. “Hepatitis C remains an important part of our business and with multiple ongoing studies of [the experimental pill], our strategy is unchanged.”

Robert Weisman can be reached at Follow him on Twitter @GlobeRobW.
Loading comments...

Wake up with today's top stories.

Want each day's news headlines delivered fresh to your
inbox every morning? Just connect with us
in one of the following ways:
Please enter a valid email will never post anything without asking.
Privacy Policy
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of